Claudins are transmembrane proteins that seal tight junctions, and are critical for maintaining cell-to-cell adhesion in epithelial cell sheets. However, their role in cancer progression remains largely unexplored. Here, we report that Claudin-7 (CLDN-7) expression is lower in invasive ductal carcinomas (IDC) of the breast than in normal breast epithelium, as determined by both RT-PCR (9/10) and Western analysis (6/8). Immunohistochemical (IHC) analysis of ductal carcinoma in situ (DCIS) and IDC showed that the loss of CLDN-7 expression correlated with histological grade in both DCIS (Po0.001, n ¼ 38) and IDC (P ¼ 0.014, n ¼ 31), occurring predominantly in high-grade (Nuclear and Elston grade 3) lesions. Tissue array analysis of 355 IDC cases further confirmed the inverse correlation between CLDN-7 expression and histological grade (P ¼ 0.03). This pattern of expression is consistent with the biological function of CLDN-7, as greater discohesion is typically observed in high-grade lesions. In line with this observation, by IHC analysis, CLDN-7 expression was lost in the vast majority (13/17) of cases of lobular carcinoma in situ, which is defined by cellular discohesion. In fact, inducing disassociation of MCF-7 and T47D cells in culture by treating with HGF/scatter factor resulted in a loss of CLDN-7 expression within 24 h. Silencing of CLDN-7 expression correlated with promoter hypermethylation as determined by methylation-specific PCR (MSP) and nucleotide sequencing in breast cancer cell lines (3/3), but not in IDCs (0/5). In summary, these studies provide insight into the potential role of CLDN-7 in the progression and ability of breast cancer cells to disseminate.
Introduction
Metastasis is the primary cause of fatality in breast cancer patients. Although there are believed to be numerous events contributing to the process of metastasis, it is widely accepted that the loss of cell-to-cell adhesion in neoplastic epithelium is necessary for invasion of surrounding stromal elements and subsequent metastatic events. Cell-to-cell adhesion in epithelial cell sheets is maintained mainly through two types of junctions: adherens junctions and tight junctions. Numerous studies have focused their attention on the transmembrane protein of the adherens junction, E-cadherin. These studies have shown that impairing the function of E-cadherin can cause cell dispersion and confer invasive properties in various cell types. Owing to these abilities, E-cadherin is believed to function as a tumor suppressor in numerous tissues and has been shown to be a useful prognostic indicator for some tumors, illustrating the importance of cell-to-cell adhesion proteins in cancer progression (Soler et al., 1995; Wheelock et al., 2001) .
Tight junctions, unlike adherens junctions, are solely involved in cell-to-cell adhesion and serve two main functions in epithelial cell layers. First, they prevent the paracellular transport of solutes and ions, maintaining concentration gradients driving transcellular transport. Second, tight junctions prevent the diffusion of membrane proteins and lipids from the apical layer to the basolateral layer of an epithelial cell sheet, helping to maintain cell polarity (Mitic and Anderson, 1998) . Although tight junctions have clearly been shown to play a role in cell-to-cell adhesion, their potential role in cancer progression has been scarcely studied. This may be due, in part, to the lack of knowledge concerning the protein components of these junctions. However, in 1998, Tsukita et al. discovered a new family of tight junction proteins named Claudins (CLDNs) (Furuse et al., 1998) . Currently, there are 20 known members of the CLDN family (Mitic et al., 2000) .
CLDNs contain four transmembrane domains and two extracellular loops through which they bind to CLDNs on adjacent cells . CLDNs have also been shown to bind to the tight junction protein ZO-1 through their carboxyl terminus (Itoh et al., 1999) . Interestingly, ZO-1 is believed to interact with several proteins involved in cell signaling and transcriptional regulation (Balda and Matter, 2000; Mitic et al., 2000) . These studies suggest that CLDNs may play an indirect role in cell signaling and transcriptional regulatory events. Most importantly, studies have shown CLDNs to be the main sealing proteins of the tight junction .
Although changes in the permeability of tight junctions have been observed in several types of cancer, little is known about the role of CLDNs in cancer. In one such investigation, CLDN-1 cDNA levels were found to be decreased in a number of breast tumors and breast cancer cell lines (Kramer et al., 2000) . Kramer et al. (2000) went on to examine the genetic status of CLDN-1 in a large number of sporadic and hereditary breast cancers, but found no genetic alterations that could explain this loss or provide evidence supporting the involvement of aberrant CLDN-1 in breast tumorigenesis.
Here we present, for the first time, data showing that expression of the tight junction protein CLDN-7 is lost in ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), and invasive ductal carcinoma (IDC) of the breast relative to normal mammary epithelium. Loss of CLDN-7 closely associates with the discohesive architecture typically observed in high-grade lesions, suggesting a potential functional role for CLDN-7 in breast cancer progression. While the mechanism of loss of CLDN-7 in breast cancer cell lines could be ascribed to promoter hypermethylation (Jones and Baylin, 2002) , this was not found to be the case in primary IDCs. Taken together, these studies suggest that the loss of CLDN-7 may aid the dissemination of cancer cells.
Results
Expression of CLDN-7 mRNA in IDC and normal mammary epithelium A SAGE and cDNA microarray analysis performed previously in our laboratory had suggested that CLDN-7 was overexpressed in breast cancer cell lines and IDCs of the breast relative to cultured finite lifespan human mammary epithelial cells (HMEC) (Nacht et al., 1999) . We initiated validation studies by directly comparing the expression of a number of differentially expressed mRNAs in IDCs using semiquantitative RT-PCR analysis. Confirming data from microarray analysis (Nacht et al., 1999) , CLDN-7 expression was undetectable by RT-PCR in finite lifespan HMECs expanded in tissue culture, 16637 and 04372 (Figure 1) , and in HMEC 184, 184A1 (early and late passage) and 184B1 (data not shown). Contrary to our expectation, however, easily detectable to high levels of CLDN-7 mRNA expression were seen in seven of seven uncultured luminal and myoepithelial cell populations derived from normal mammoplasty specimens. Also, nine of 10 IDCs showed low or undetectable levels of CLDN-7 mRNA (Figure 1a ). These observations were in direct contrast to our published data (Nacht et al., 1999) , where we had reported that at least 50% of primary tumors express levels of CLDN-7 mRNA that were significantly higher than cultured finite lifespan HMEC.
One possible explanation for these contradictory findings could be the choice of HMEC used to compare expression profiles between normal and tumor samples. In our study, as in many other comparative gene expression profiling studies (Fujii et al., 2002; Iacobuzio-Donahue et al., 2002) , we had used mortal HMEC expanded in tissue culture as our source of normal breast epithelium. We considered the possibility that placing the cells in tissue culture, albeit short term, may have altered their expression profile and resulted in a loss of CLDN-7 expression. To test this possibility, we determined the expression of CLDN-7 in two immortalized and four finite lifespan HMEC cultured in vitro, six uncultured HMEC derived from three normal mammoplasty specimens, and 10 breast cancer cell lines by realtime PCR analysis (Figure 1b) . A striking difference in CLDN-7 mRNA expression was observed between the six tissue cultured cell lines (n ¼ 2) and strains (n ¼ 4) and the six uncultured HMEC. HMEC cultured in vitro showed very low to undetectable levels of CLDN-7 mRNA expression, while an average of nearly 1000-fold higher levels were observed in uncultured HMEC, of both luminal and myoepithelial subfractions. Thus, the erroneous conclusion of CLDN-7 overexpression in primary tumors likely arose as a consequence of using cultured HMEC (which expressed extremely low levels of CLDN-7 mRNA) as a basis for comparison. Relative to CLDN-7 mRNA levels in uncultured HMEC, however, CLDN-7 expression in all 10 breast cancer cell lines was lower by 10-1000-fold. Thus, although immaterial for many other genes (Ferguson et al., 2000; Evron et al., 2001a, b; Loeb et al., 2001) , placing HMEC in tissue culture had the profound effect of silencing CLDN-7 expression. When used as controls for comparative gene expression studies, such tissue-culture-based alterations could lead to inaccurate interpretation of data.
Generation and characterization of CLDN-7 polyclonal antibody
To study expression of CLDN-7 protein in breast tissues, we generated a rabbit polyclonal antibody against a peptide corresponding to the C-terminus of CLDN-7. This region of the protein shares little sequence similarity with other members of the CLDN family. Next, we used the C-terminal CLDN-7 peptide in enzyme-linked immunosorbent assay (ELISA) to test for the presence of CLDN-7 antibody in rabbit sera, and affinity purified the CLDN-7 antibody using the peptide against which it was raised. Western analysis of CLDN proteins generated in vitro showed that the antibody reacted with CLDN-7 while showing no crossreactivity with CLDN-3 or -4 (Figure 2a ). Conversely, antibodies to CLDN-3 and -4 did not detect CLDN-7 protein, but detected their cognate protein.
Further, preincubation of CLDN-7 antibody with the C-terminal peptide was able to compete out binding to CLDN-7 protein in Western analysis (data not shown). Immunofluorescence studies using the affinity purified antibody showed colocalization of CLDN-7 with the tight junction protein ZO-1 at the cell membrane (Figure 2b ). Whether the unique red spots in the cytoplasm represent nonspecific staining or CLDN-7 localized in cell organelles is not yet known. These spots were not localized to mitochondria, however, since they did not colocalize with organelles stained by using the MitoTracker Red dye (Molecular Probes, Eugene ORE).
Expression of CLDN-7 protein in IDC and normal mammary epithelium
To determine whether protein expression reflected that of CLDN-7 mRNA expression as obtained by RT-PCR, we performed Western analysis on a panel of 10 breast cancer cell lines, eight IDCs, and four samples of mammary organoids isolated from reduction mammoplasty specimens of normal women. Consistent with real-time quantitative RT-PCR results (Figure 1b) , Western analysis of a panel of 10 breast cancer cell lines showed a close correlation between CLDN-7 protein ( Figure 3a ) and CLDN-7 mRNA expression. Cell lines that showed low or no detectable mRNA (MDA-MB-435, MDA-MB-231, and HS578T) had no detectable protein, while the remaining seven cell lines showed detectable CLDN-7 expression (Figure 3a ). Also consistent with RT-PCR (Figure 1a) , CLDN-7 expression in six of eight IDCs was significantly lower than in four samples of epithelial organoids obtained by enzymatic digestion of normal mammoplasty specimens (Figure 3b ). Owing to the heterogeneity of cell types in breast tissue and the fact that only the epithelial cell component expresses CLDNs, it was necessary to determine if the loss of CLDN-7 expression observed in breast cancer tissues relative to normal mammary epithelium was simply because of a difference in epithelial cell content. Therefore, we performed immunohistochemical (IHC) analysis on several of the same IDC cases that had been tested by Western analysis (indicated by * in Figure 3b ). In each case, the CLDN-7 staining pattern was compared to that in adjacent normal epithelium as an internal positive control. Surrounding fibroblasts and adipocytes served as negative controls since these cells do not express CLDN proteins. As expected for a tight junction protein, CLDN-7 staining was restricted to epithelial cells with the strongest expression concentrated at the cell membrane (Figure 3c ), although diffuse staining in the cytoplasm was also observed. Consistent with the Western analysis results (Figure 3b ), the level of CLDN-7 staining was greatly reduced in all three IDCs tested as compared to adjacent normal epithelium ( Figure 3c ).
Expression of CLDN-7 in ductal carcinoma in situ and IDC
To assess the potential value of loss of CLDN-7 as a prognostic indicator for breast cancer, we determined its expression pattern in a series of in situ and invasive breast carcinomas by IHC analysis. As DCIS is believed to be a direct precursor to IDC, we first examined the CLDN-7 staining pattern in a range of DCIS cases, from nuclear grade 1 (low grade) through 3 (high grade). In each case, the staining pattern of CLDN-7 in DCIS was compared to that in adjacent normal epithelium, where staining was predominantly membranous. IHC analysis showed no changes in CLDN-7 expression in either grade 1 (0/10) or grade 2 (0/14) cases, while 71% of grade 3 cases (10/14) showed a loss of its expression ( Figure 4 , Table 1 ). Thus, we observed that CLDN-7 expression in Figure 2 Characterization of CLDN-7 polyclonal antibody. (a) Affinity-purified CLDN-7 pAb reacts with human CLDN-7 protein, while showing no crossreactivity with human CLDN-3 or -4. Human CLDN-3, -4, and -7 were cloned into pCR 3.1 (Invitrogen) and proteins were generated in vitro using cDNA clones in the TnT Quick Coupled Transcription/Translation System as determined by Western analysis using antibodies specific for CLDN-3 and -4 (Zymed). Western analysis was performed on equal amounts of protein from TnT reactions using CLDN-7 antibody producing a single band at the predicted size of approximately 23 kDa, but not with antibodies specific to CLDN-3 or -4 (b) CLDN-7 protein localizes to the cell membrane, colocalizing with ZO-1. MCF-7 cells were grown to confluence on a chambered slide, and probed with CLDN-7 and ZO-1 antibodies. CLDN-7 and ZO-1 proteins were visualized both individually (red ¼ CLDN-7, green ¼ ZO-1) and as a composite (yellow ¼ colocalization by confocal microscopy at a magnification of Â 600
Loss of CLDN-7 in ductal carcinoma SL Kominsky et al Figure 3 CLDN-7 protein expression in breast cancer cell lines, and IDC relative to normal mammary epithelium. (a) CLDN-7 protein expression in breast cancer cell lines. Western analysis was performed on equal amounts of protein from total cell lysates using CLDN-7 and b-actin antibodies. (b) IDC and normal mammary organoid tissue were homogenized, and total protein was extracted. Western analysis was performed on equal amounts of protein from cell lysates using CLDN-7 and b-actin antibodies. (c) IHC analysis was performed on paraffin-embedded sections of human breast cancer tissues 079, 126, and 973 identified by an asterisk in (a) using CLDN-7 antibody. CLDN-7 protein in human breast cancer tissues (T) and adjacent normal mammary epithelium (N) were visualized using DAB. Note the membrane staining in normal breast epithelium (inset). Sections were counterstained with hematoxylin and visualized by light microscopy ( Â 200)
Loss of CLDN-7 in ductal carcinoma SL Kominsky et al DCIS was inversely correlated with nuclear grade (Po0.001).
We next examined the CLDN-7 staining pattern in IDCs ranging from Elston grade 1 (low grade) through 3 (high grade), which was compared in each case to that seen in the normal epithelium present on the same section. Few grade 1 (1/6) or grade 2 (3/12) IDC cases showed a loss of CLDN-7 expression, while 77% of grade 3 cases (10/13) showed a significant loss of staining ( Figure 4 , Table 1 ). Thus, CLDN-7 expression in IDC was found to be inversely correlated with histological grade (P ¼ 0.014).
CLDN-7 immunoreactivity in IDC was further studied by tissue array analysis ( Figure 5 ). Of the 612 total cases of IDC on the tissue array, 100 Elston grade 1, 140 Elston grade 2, and 115 Elston grade 3 cases were evaluable and showed an inverse correlation between CLDN-7 expression and histological grade (P ¼ 0.03). This finding was consistent with the results of the case-by-case analysis Figure 4 CLDN-7 expression is unchanged in low-grade DCIS (nuclear grades 1-2) and IDC (Elston grades 1-2), but lost in highgrade DCIS (nuclear grade 3) and IDC (Elston grade 3) (T) relative to adjacent normal mammary epithelium (N). IHC analysis was performed on paraffin-embedded sections of human breast tissue using CLDN-7 antibody. CLDN-7 protein was visualized using DAB. Sections were counterstained in hematoxylin and visualized by light microscopy ( Â 200). Note membrane staining of normal breast epithelium (inset) Table 1 ). No correlation between CLDN-7 expression and estrogen/progesterone receptor status, age, tumor size, or lymph node status was found by tissue array analysis. This last result was contrary to our case-by-case analysis, where seven of 10 IDCs with a positive lymph node status showed a loss of CLDN-7 expression. While the utility of tissue arrays cannot be underestimated since it allows for very high sample throughput, the lack of an internal control (normal epithelium) for each tumor sample, combined with the small sampling represented in each tissue punch could lead to a greater error in determining gene expression. In our study, these factors may be responsible for the lack of correlation with lymph node status in tissue arrays when compared to case-by-case analysis. This source of error is being minimized in newer generations of tissue arrays, which contain several punches from the same tumor tissue, and also from their normal margins. Thus, at the present time, it is critical to perform a case-by-case analysis alongside tissue array analysis.
Expression of CLDN-7 in LCIS
If CLDNs play a functional role in cell-to-cell adhesion, breast lesions that are typified by scattered cells should express very low levels of CLDN-7.
In agreement with this notion, IHC analysis of LCIS, a lesion whose defining and characteristic feature is discohesion, showed a loss of CLDN-7 expression in 76% (13/17) of cases. This contrasted significantly (P ¼ 0.001) with DCIS, where its loss is seen in only 26% (10/38) of cases irrespective of grade ( Figure 6 , Table 1 ).
Effect of HGF/scatter factor on CLDN-7 expression
A direct demonstration of the inverse correlation between CLDN-7 expression and cell-to-cell adhesion was sought by the treatment of breast cancer cell lines with hepatocyte growth factor/scatter factor (HGF/ scatter factor). HGF is well known for its ability to decrease cell-to-cell adhesion and stimulate cell migration (Jiang et al., 1999) . Breast cancer cell lines MCF-7 and T47D, which express high levels of CLDN-7 localized at the tight junction (shown for MCF-7 in Figure 2b ), were treated with HGF/scatter factor for a period of 24 h. By Western analysis, a dramatic downregulation of CLDN-7 was observed in MCF-7, and to a lesser extent in T47D cells (Figure 7 ). These data provide further direct evidence that loss of CLDN-7 occurs concurrently with loss of cell-to-cell adhesion. Loss of CLDN-7 in ductal carcinoma SL Kominsky et al
Mechanism of loss of CLDN-7 expression in breast cancer
To investigate the mechanism responsible for the loss of CLDN-7 expression, we first wanted to rule out the presence of mutations in the CLDN-7 mRNA (Accession #AJ011497) sequence. Nucleotide sequencing of the full-length cDNA revealed no mutations in the CLDN-7 coding sequences in all 11 primary IDCs tested (data not shown). Among the 11 tumors, six expressed very low or no CLDN-7 mRNA as determined by semiquantitative RT-PCR analysis (Figure 1a) .
The presence of CG-dinucleotide-rich sequences in the promoter region of genes is quite often a signature denoting that hypermethylation may be a potential mechanism for gene silencing (Ferguson et al., 2000; Evron et al., 2001a, b; Loeb et al., 2001; Jones and Baylin, 2002) . The CLDN-7 promoter contains a CpGrich region extending from À20 to À900 bp upstream of the translational start site (Accession #11425795). Therefore, we investigated the promoter region of the CLDN-7 gene. Methylation-specific PCR (MSP) analysis was performed on DNA from six breast cancer cell lines. The three breast cancer cell lines that show no Figure 6 CLDN-7 expression is lost in LCIS (L) relative to adjacent normal mammary epithelium (N). IHC analysis was performed on paraffin-embedded sections of human breast tissue using CLDN-7 antibody. CLDN-7 protein was visualized using DAB. Sections were counterstained in hematoxylin and visualized by light microscopy ( Â 200)
Loss of CLDN-7 in ductal carcinoma SL Kominsky et al detectable CLDN-7 expression (HS578T, MDA-MB-231, and MDA-MB-435) contained hypermethylated promoter sequences, while the three that express CLDN-7 (T47D, MCF-7, and MDA-MB-468) were unmethylated in the same region ( Figure 8a ). This correlation between the loss of CLDN-7 expression and promoter hypermethylation was further confirmed by sequencing a 300 bp region (containing a dense region of 25 CpG dinucleotides, and included the CGrich region analysed by MSP) of the CLDN-7 promoter, PCR-amplified from sodium-bisulfite-treated DNA. All 25 CpGs were methylated in HS578T, MDA-MB-231, and MDA-MB-435 cells, while MCF-7 cells contained no methylated CpGs (data not shown). Lastly, treatment of HS578T and MDA-MB-435 cells with the demethylating agent, 5-aza-dC, resulted in the re-expression of CLDN-7 ( Figure 8b) ; thus, providing another line of evidence supporting the premise that hypermethylation is a major mechanism responsible for silencing expression of CLDN-7 in breast cancer cell lines. Next, to determine if hypermethylation-mediated silencing of CLDN-7 expression is functional in primary breast cancer as well, we performed MSP analysis on DNA from IDCs. As expected, the sample of normal mammary organoid, N65, and two IDC samples that express CLDN-7 were unmethylated in this region. However, contrary to our findings in breast cancer cell lines, MSP analysis of the CLDN-7 promoter in the five IDCs that have lost CLDN-7 expression also showed completely unmethylated promoter sequences (Figure 8c ). Since MSP analyzes only a few CpGs in the promoter, we sequenced the 300 bp segment of the promoter described above. Sequencing of sodium-bisulfite-treated DNA from IDCs 079 and 973 showed no methylated CpGs (data not shown).
Thus, the evidence provided by MSP, nucleotide sequencing analysis, and re-expression of genes following 5-aza-dC treatment, strongly support the notion that promoter hypermethylation of CLDN-7 is the underlying mechanism for loss of its expression in breast cancer cell lines. However, this is not the case for primary tissue, and alternative mechanisms need to be investigated for loss of CLDN-7 in primary breast tumors.
Discussion
It is widely accepted that the loss of cell-to-cell adhesion is an early event in the process of metastasis, allowing the liberation of individual cancer cells from the primary tumor. Although a functional role for CLDN-7 in breast cancer has not yet been established, there is evidence to support its role in cell-to-cell adhesion, making it plausible that its loss may play a role in metastasis. In this study, we have shown that the level of expression of CLDN-7 mRNA and protein is significantly lower in the majority of breast cancer cell lines and in primary breast carcinomas, than in normal mammary epithelium. By immunohistochemistry, CLDN-7 expression was lost in the majority of high-grade IDCs (Table 1) , which are most likely associated with nodal metastasis; this suggests a potential role for CLDN-7 expression in the development of metastasis. Interestingly, in case-by-case analysis, seven of 10 IDCs in our panel that showed a loss of CLDN-7 staining had a positive lymph node status. Although small, these preliminary IHC studies show that CLDN-7 expression in primary IDCs correlates with the ability of the tumor to metastasize. Finally, we showed that hypermethylation of the promoter region correlated with loss of expression of CLDN-7 in breast cancer cell lines, but not in primary breast cancers.
Since high-grade IDCs form fewer tubules and therefore demonstrate less cohesion, it was possible that the expression of all 20 CLDNs would be lost during this transition. However, in several IDC cases in which we observed a loss of CLDN-7 expression, we have found that the levels of CLDN-1, -3, and -4 remain unchanged by both Western and IHC analyses (our unpublished findings). This suggests that the loss of CLDN-7 expression may be a specific event that is not common to all CLDNs. Still the question remains as to whether the loss of one CLDN member could have a significant impact on cell-to-cell adhesion. As numerous CLDNs exist in epithelial tissues, it is reasonable to assume that another CLDN family member may compensate for the loss of CLDN-7. However, a growing body of literature suggests that alterations in individual CLDN proteins can have unique effects in the cell. For example, CLDN-1-deficient mice have been shown to die within 1 day of birth despite the presence of CLDN-4 (Furuse et al., 2002) . The deletion of CLDN-5 has been found to be associated with velocardio-facial syndrome (Sirotkin et al., 1997) . Mutations in CLDN-14 have been shown to cause autosomal recessive deafness, while mutations in CLDN-16 have been shown to interfere with Mg 2+ and Ca 2+ resorption (Simon et al., 1999; Wilcox et al., 2001) . While the 20 known CLDNs may have common and perhaps redundant function in formation of tight junctions, proteins that interact with each CLDN may be unique Figure 7 Hepatocyte growth factor/scatter factor (HGF/scatter factor) downregulates CLDN-7 expression in human breast cancer cells. MCF-7 and T47D cells were cultured with or without 10 ng/ ml HGF/scatter factor in complete media for 24 h. Western analysis was performed on equal amounts of total cell lysate using CLDN-7 and b-actin antibodies Loss of CLDN-7 in ductal carcinoma SL Kominsky et al within specific cell types and thereby confer specificity to the action of each member of this large family of tight junction proteins.
Another important finding of this study is the inverse correlation between CLDN-7 expression and histological grade observed in both DCIS and IDC lesions, which sheds some light on the controversy surrounding the process of breast cancer progression. One possible scenario is that breast cancer progresses in a fashion similar to that of other intraepithelial neoplasias wherein DCIS lesions progress from low-grade to high-grade. High-grade DCIS lesions would then progress to lowgrade IDC lesions, which then could progress to highgrade IDCs. The fact that CLDN-7 expression was lost in the majority of high-grade DCIS lesions and highgrade IDC lesions examined, but rarely lost in low-grade IDC lesions ( Figures 4 and 5) . This suggests a model in which low-grade DCIS progresses to low-grade IDC, while high-grade DCIS progresses to high-grade IDC. This model is also supported by the known association of similar histological grades between concurrent DCIS and IDC upon histopathological examination of primary human breast tumors. While the expression pattern of CLDN-7 alone can neither definitively confirm nor deny the validity of either model, it does emphasize the need for further studies into breast cancer progression.
By both MSP and nucleotide sequencing of sodiumbisulfite-treated DNA, we have provided evidence that hypermethylation of promoter sequences is likely the underlying mechanism for the loss of CLDN-7 expression in breast cancer cell lines (Figure 8a, b) . In contrast, analysis of primary breast cancer DNA failed to show hypermethylation in the CLDN-7 promoter sequences Figure 8c ). There is precedence for this observation from our laboratory, where the promoter sequence of WT-1 was hypermethylated and correlated with loss of expression in breast cancer cell lines, but not in primary tumors (Loeb et al., 2001) . Whether growth in tissue culture requires the loss of expression of certain genes, which could be established by hypermethylation of the promoter, is a valid question. Interestingly, two of the cultured finite lifespan HMEC that lack CLDN-7 mRNA expression, 9F1403 and 184, were hypermethylated in the CLDN-7 promoter region, while two of the uncultured organoid preparations that express CLDN-7 mRNA, N65, and N34 are unmethylated in the same region (our unpublished observations).
In conclusion, this study shows that expression of the tight junction protein CLDN-7 was lost in both preneoplastic and invasive ductal carcinoma of the breast, occurring predominantly in high-grade lesions. CLDN-7 expression was also frequently lost in LCIS, correlating with the increased cellular discohesion observed in LCIS. Additionally, the majority of IDC cases displaying a low CLDN-7 expression had a positive lymph node status. Taken together, these findings suggest that the loss of CLDN-7 may aid in tumor cell dissemination and augment metastatic potential.
Materials and methods

Cell lines, organoids and tumors
Most cell lines were obtained from American Type Culture Collection (Rockville, MD, USA), and cultured according to conditions specified. Breast cancer cell lines 21PT and 21MT were kindly provided by Dr Vimla Band (New England Medical Center, Boston, MA, USA). Finite lifespan HMEC 184, immortalized HMECs 184A1 (early and late passages), and 184B5 were kindly gifted by Dr Martha Stampfer (Lawrence Berkeley Laboratories, Berkeley, CA, USA). Finite lifespan HMECs 9F1403, 04372, 16637 were purchased from Clonetics (Rockville, MD, USA). HMEC strain 11-24 was kindly gifted by Dr Steven Ethier (University of Michigan, Ann Arbor, MI, USA). Mammary organoid samples, N1, N34, N65, and N74, kindly provided by Dr Sigmund A. Weitzman (Northwestern University Medical School, Chicago, IL, USA), were prepared from reduction mammoplasty specimens of women with no abnormalities in the breast as described (Bergstraessar and Weitzman, 1993) . Briefly, the specimens were enzymatically digested into duct-like structures (organoids), filtered, histologically confirmed to contain greater than 80% epithelial cells, and frozen at À701C until use (Bergstraessar and Weitzman, 1993) . Highly purified (95-99%) luminal and myoepithelial cells, kindly provided by Dr Lakjaya Buluwela (Division of Medicine, Imperial College School of Medicine, London W120NN, UK), were isolated by differential centrifugation and fluorescence-activated cell sorting of enzymatically digested normal mammoplasty specimens (Gomm et al., 1995) . Paraffin blocks of DCIS, LCIS, and IDCs of the breast were obtained from the Surgical Pathology files of the Johns Hopkins Hospital, observing institutional guidelines for acquisition of such specimens.
Generation of CLDN-7 antibody
A synthetic peptide corresponding to the C-terminus of CLDN-7 protein conjugated to the carrier protein, keyhole limpet hemocyanin (KLH) was generated by Mimotopes (Raleigh, NC, USA). Polyclonal rabbit antipeptide antibodies were raised and sera were collected. CLDN-7 polyclonal antibody was then affinity purified using the Aminolink Immobilization kit (Pierce, Rockford, IL, USA) and the peptide against which the antibody was raised. To test the affinity-purified CLDN-7 antibody for crossreactivity with other CLDN proteins, human CLDN-3-, -4, and -7 were cloned into pCR 3.1 (Invitrogen, Carlsbad, CA, USA). CLDN-3, -4, and -7 proteins were generated in vitro using cDNA clones in the TnT Quick Coupled Transcription/ Translation System (Promega, Madison, WI, USA). CLDN-7 antibody is available through Zymed, catalog # 34-9100 h.
Immunofluorescence microscopy
Cells (1 Â 10 5 ) were plated in eight-chamber slides (Nunc, Naperville, IL, USA) and cultured until confluent. Cells were rinsed in phosphate-buffered saline (PBS) and fixed in 2% paraformaldehyde diluted in PBS for 15 min. Cells were then permeabilized in 0.5% Triton-X diluted in PBS for 5 min. Following permeabilization, cells were incubated in 20 mg/ml bovine serum albumin for 1 h at room temperature. Rabbit polyclonal CLDN-7 antibody diluted at 1 : 500 was then added to the cells and incubated at room temperature for 1 h. Subsequently, cells were incubated with mouse monoclonal ZO-1 antibody (Zymed, San Francisco, CA, USA) for 1 h at room temperature. Cells were then incubated with anti-rabbit IgG conjugated to Alexafluor 568 and anti-mouse IgG conjugated to Alexafluor 488 (Molecular Probes, Eugene, OR, USA) for 1 h at room temperature. Before visualizing the cells, sections were coverslipped and sealed. Confocal microscopy images were obtained using a Nikon PCM 2000.
Immunohistochemistry
Paraffin-embedded sections and breast tumor array sections were deparaffinized in xylene and rehydrated through graded ethanols. Antigen retrieval was performed by immersing sections in 0.01 m sodium citrate, pH 6.0, and boiling by microwave for 20 min. Sections were then cooled to room temperature and endogenous peroxidase activity was quenched by immersing in 0.3% hydrogen peroxide for 30 min. Blocking was then performed by incubation in diluted normal goat serum (Vectastain kit, Vector, Burlingame, MI, USA) as per the manufacturer's instructions. Sections were then incubated with rabbit polyclonal CLDN-7 at a 1 : 500 dilution for a period of 16 h. Diluted biotinylated anti-rabbit IgG (Vectastain kit) was added to the sections and incubated for 30 min. Vectastain ABC reagent was then added for 30 min. CLDN-7 protein was visualized using 3,3 0 -diaminobenzamidine (DAB) as per the manufacturer's instructions (Vector). Sections were then counterstained in hematoxylin (Richard-Allan Scientific, Kalamazoo, MI, USA) for 10 s. Lastly, sections were dehydrated through graded ethanols, cleared in xylene, mounted, and coverslipped. Images were acquired by light microscopy.
Statistical analysis of CLDN-7 expression
IHC staining of CLDN-7 in DCIS, LCIS, and IDC lesions was scored relative to adjacent normal mammary epithelium as positive (no change in expression) or negative (loss of expression). Comparisons of CLDN-7 expression across grade were made by tabulating scores for CLDN-7 staining according to histological grade (Nuclear or Elston grades 1, 2, or 3). Two-sided Fisher's exact tests were used to assess statistical significance. Although grade is an ordinal variable, the analysis treated it as nominal categorical. As such, P values are slightly conservative. Inverse correlation implies that as histological grade tends to higher values, CLDN-7 is less likely to be expressed.
Methylation-specific PCR
Genomic DNA (1 mg) was treated with sodium bisulfite as previously described (Ferguson et al., 2000) and was analysed by MSP using primer sets located within a CpG-rich area in the CLDN-7 promoter (Accession #11425795). Primers specific for unmethylated DNA were 5 0 -TGGGGAAAGGG TGGTGTTG-3 0 (sense, À831 to À812) and 5 0 -TTACC-CAATTTTAACCACCAC-3 0 (antisense, À670 to À649) yielding a 182 bp product. Primers specific for methylated DNA were 5 0 -GACGTTAGGTTATTTTCGGTC-3 0 (sense, À550 to À529) and 5 0 -AAACGCGTTTCTAAACGCCG-3 0 (antisense, À350 to À330) yielding a 220 bp product. The PCR conditions were as follows: one cycle of 951C for 5 min 'hot start,' then addition of 1 ml Taq polymerase (RedTaq, Sigma, St Louis, MO, USA); 35 cycles of 951C for 30 s, 561C for 30 s, and 721C for 45 s; and one cycle of 721C for 5 min. PCR samples were resolved by electrophoresis on a 1.5% agarose gel.
5-aza-dC treatment
Cells were seeded in a 100 mm plate at a density of 1 Â 10 6 cells. After 24 h, cells were treated with 0.75 mm 5-aza-dC (Sigma) (Ferguson et al., 2000; Evron et al., 2001a, b) . Total cellular DNA and RNA were isolated at 0, 3, and 5 days after addition of 5-aza-dC.
RT-PCR
Total RNA was extracted using TRI REAGENT BD by the manufacturer's protocol (Molecular Research Center, Cincinnati, OH, USA). cDNA was generated by reverse transcription. Reactions contained 2 mg DNAse-treated RNA, 0.25 mg/ ul pdN6 random primers (Life Technologies, Rockville, MD, USA), 1 Â first-strand buffer (Life Technologies), 1 mm of each deoxynucleotide triphosphate (Life Technologies), 200 units Superscript reverse transcriptase (Life Technologies), and were incubated for 1 h at 371C, followed by heat inactivation at 701C for 15 min. PCR was performed using the primers 5 0 -CCACTCGAGCCCTAATGGTG-3 0 (sense) and 5 0 -GGTA CCCAGCCTTGCTCTCA-3 0 (anti-sense) for CLDN-7 (Accession #AJ011497). Coamplified products of 36B4, a 'housekeeping' ribosomal protein gene, were used as an internal control, using primers 5 0 GATTGGCTACCCAACTGTTG-CA-3 0 and 5 0 -CAGGGGCAGCAGCCACAAAGGC-3 0 for sense and antisense, respectively. The 25 ml reactions contained 1X buffer (2X reaction mix, Life Technologies), 1 ml cDNA, and 100 nm of each primer. The PCR conditions were: one cycle of 941C for 1 min, 'hot start,' followed by addition of one unit of Taq polymerase (RedTaq, Sigma), 35 cycles of 941C for 30 s, 591C for 30 s, 721C for 45 s, and finally one cycle of 721C for 5 min. PCR samples were resolved by electrophoresis on a 1.5% agarose gel.
Real-time PCR
Total RNA was extracted and cDNA was generated by reverse transcription as described above. CLDN-7 and GAPDH (a 'housekeeping' gene) were amplified individually using a 96-well plate and optical caps (PE Applied Biosystems, Foster City, CA, USA) with a 25 ml final reaction volume containing 250 nmol/l sense and antisense primer, 200 nmol/l probe, 2.5 mm MgCl 2 , one unit Amplitaq Gold, 200 mmol/l each of dATP, dCTP, dTTP, and dGTP in 1X Taqman Buffer A. Reaction mixtures were preheated to 951C for 10 min, followed by 40 cycles at 951C for 15 s and 601C for 1 min. The primer and probe sequences are as follows: CLDN-7 (sense) 5 0 -AAAG TGAAGAAGGCCCGTATAGC-3 0 , CLDN-7 (antisense) 5 0 -GCTACCAAGGCGGCAAGAC-3 0 , CLDN-7 (probe) 5 0 -CC ACGATGAAAATTATGCCTCCACCCA-3 0 , GAPDH (sense) 5 0 -CCCATGTTCGTCATGGGTGT-3 0 , GAPDH (antisense) 5 0 -TGGTCATGAGTCCTTCCACGATA-3 0 , and GAPDH (probe) 5 0 -CTGCACCACCAACTGCTTAG-3 0 . All PCR reagents, including primers and probes, were purchased from PE Applied Biosystems.
Sequencing of sodium-bisulfite-treated DNA DNA from peripheral white blood cells, IDCs, and breast cancer cell lines was treated with sodium bisulfite as previously described (Ferguson et al., 2000) . Briefly, the DNA was purified and a CpG-rich promoter region was amplified by PCR using the following primers: 5 0 -GTGATTTTGGTGTT-TAGGT-3 0 (sense primer with start at À675) and 5 0 -ATCCCAAAATATCCTAAACTA-3 0 (antisense primer with start at À375), which generated a 300 bp PCR product. The product was purified using a Qiagen PCR purification kit (Qiagen Corp) and sequenced using the antisense primer.
Western blotting
IDC of the breast and normal mammary organoid tissue was homogenized and total protein was extracted using lysis buffer consisting of 15% glycerol, 5% SDS, and 250 mm Tris-HCl, pH 6.7. Equal amounts of protein from cell lysates were resolved using 12% SDS-PAGE (Invitrogen, Carlsbad, CA, USA). Protein was then transferred to ECL nitrocellulose membranes (Amersham, Arlington Heights, IL, USA). Following Western transfer, membranes were probed with CLDN-3, 4 (Zymed), CLDN-7, or b-actin (Amersham) antibody diluted 1 : 1000 (CLDN-3, 4, and 7) or 1 : 5000 (b-actin). Horseradish peroxidase-conjugated antibody against rabbit or mouse IgG (Amersham) was used at 1 : 1000 and binding was revealed using enhanced chemiluminescence (Amersham).
Abbreviations CLDN, Claudin; IDC, invasive ductal carcinoma; RT-PCR, reverse transcription-PCR; IHC, immunohistochemical analysis; DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ; HGF/scatter factor, hepatocyte growth factor/scatter factor; KLH, keyhole limpet hemocyanin; MSP, methylationspecific PCR; DAB, 3 3 0 -diaminobenzamidine; GAPDH, glyceraldehyde phosphate dehydrogenase; 5-aza-dC, 5 0 -aza-2 0 -deoxycytidine; HMEC, human mammary epithelial cells.
